Celebrating 25 years of the Swiss Biotech Association

Tuesday, April 25, 2023 @ 7:00 am

Some major achievements of Swiss biotech innovation…

1998 Monoclonal antibodies Trastuzumab
Herceptin, Roche, breast cancer
1998 Interferon beta-1a
Rebif, Serono, multiple sclerosis
2001 Bosentan
Tracleer, Actelion, pulmonary arterial hypertension (PAH)
2003 Kinase inhibitors Imatinib
Gleevec, Novartis, cancer
2013 CRISPR-Cas9 gene editing
CRISPR Therapeutics using technology to treat genetic diseases
2013 Humanized anti-CD20 monoclonal antibody Obinutuzumab
Gazyva, Glycart/Roche, chronic lymphocytic leukaemia
2017 CAR-T cell therapy Tisagenlecleucel
Kymriah, Novartis, leukaemia
2019 Humanized single chain antibody anti-VEGF Brolucizumab
Beovu, Esbatech/Novartis, wet-AMD
2019 Gene therapy Onasemnogene abeparvovec-xioi
Zolgensma, Novartis, paediatric spinal muscular atrophy (SMA)
2021 Aducanumab
Aduhelm, Neuroimmune/Biogen, Alzheimer’s disease
2023 DDM Genomics and Multimodal platform
SOPHiA GENETICS hits milestone of One Million Genomic Profiles analyzed by the SOPHiA DDM™ platform

Most of these highlights were achieved in international collaboration and benefit patients around the world. They do not represent a comprehensive list but rather a selection that emphasizes the diversity of modalities that have been developed over time and the broad range of medical needs they help to address.

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

SOTIO enters into agreement with Biocytogen to expand antibody-drug conjugates pipeline

Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite platform Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million
July 16, 2024

Asceneuron secures USD 100 million financing to advance therapeutics in neurodegenerative diseases

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical developme
July 16, 2024

LimmaTech appoints Staph Leavenworth Bakali as Chairman of the Board

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors. Mr. Leavenworth Bakali brings over 30 years of senior executive and board-level experience in the life science and healthcare industries.
July 1, 2024

Newron flash update “A pivotal year” - potential of schizophrenia drug

June 27, 2024

Ymmunobio and EVIIVE: Collaboration to develop advanced liquid biopsy for cancer patients

Ymmunobio and EVIIVE are pleased to announce their strategic collaboration to develop an innovative liquid biopsy technology utilizing extracellular vesicles (EVs). This partnership marks a significant advancement in precision medicine, aiming to enhance disease detection and patient monitoring accuracy and efficacy.
June 24, 2024